

Annals of the Rheumatic Diseases

The EULAR Journal



Annual European Congress of
RHEUMATOLOGY

EULAR 2017

Madrid, 14–17 June 2017

Abstracts

Annals of the Rheumatic Diseases

Annual European Congress of Rheumatology

14 – 17 June, 2017

Madrid, Spain

Abstracts

The EULAR Journal

Editor

Tore K Kvien (Norway)

Associate Editors

Francis Berenbaum (France)
Johannes Bijlsma (The Netherlands)
Dimitrios Boumpas (Greece)
Gerd Burmester (Germany)
Mary Crow (USA)
Iain McInnes (UK)
David Pisetsky (USA)

Methodological and Statistical Advisor

Stian Lydersen (Norway)

Graphical Advisor

Maarten Boers (The Netherlands)

Social Media Advisors

Alessia Alunno (Italy)
Mary Canavan (Ireland)
Meghna Jani (UK)
Elena Nikiphorou (UK)
Paul Studenic (Austria)

Guidelines for Authors and Reviewers

Full instructions are available online at <http://ard.bmj.com/pages/authors>. Articles must be submitted electronically at <http://mc.manuscriptcentral.com/ard>. Authors retain copyright but are required to grant ARD an exclusive licence to publish. (<http://authors.bmj.com/submitting-your-paper/copyright-and-authors-rights>).

Annals of the Rheumatic Diseases publishes original work on all aspects of rheumatology and disorders of connective tissue. Laboratory and clinical studies are equally welcome

Editorial Board

Daniel Aletaha (Austria)
Matthew Brown (Australia)
Loreto Carmona (Spain)
Carlo Chizzolini (Switzerland)
Bernard Combe (France)
Philip Conaghan (UK)
Maurizio Cutolo (Italy)
László Czirják (Hungary)
Nicola Dalbeth (New Zealand)
Oliver Distler (Switzerland)
Thomas Dörner (Germany)
Dirk Elewaut (Belgium)
Gary Firestein (USA)
David Fox (USA)
Sherine Gabriel (USA)
Mary Goldring (USA)
Juan Gómez-Reino (Spain)
Walter Grassi (Italy)
Wolfgang Gross (Germany)
Francis Guillemin (France)
Ahmet Gül (Turkey)
Kåre Birger Hagen (Norway)
Frederic Houssiau (Belgium)
Tom Huizinga (The Netherlands)
Roland Jonsson (Norway)
Mariana Kaplan (USA)
George Kollias (Greece)
Robert Landewé (The Netherlands)
Zhan-Guo Li (China)
Rik Lories (Belgium)
Ingrid Lundberg (Sweden)
Gary MacFarlane (UK)
Xavier Mariette (France)

Advisory Committee

Wim van den Berg (The Netherlands)
Stefano Bombardieri (Italy)
Ferdinand Breedveld (The Netherlands)
Leslie Crofford (USA)
Michael Doherty (UK)
Maxime Dougados (France)
Paul Emery (UK)
Daniel Furst (USA)
Steffen Gay (Switzerland)
Désirée van der Heijde (The Netherlands)
Marc Hochberg (USA)
Joachim Kalden (Germany)
Edward Keystone (Canada)
Lars Klareskog (Sweden)
Peter Lipsky (USA)

Alberto Martini (Italy)
Włodzimierz Maslinski (Poland)
Marco Mattucci Cerinic (Italy)
Dennis McGonagle (UK)
Pier-Luigi Meroni (Italy)
Pierre Miossec (France)
Timothy Niewold (USA)
Mike Nurmohamed (The Netherlands)
Monika Østensen (Switzerland)
Mikkel Østergaard (Denmark)
Constantino Pitzalis (UK)
Berent Prakken (The Netherlands)
Lars Rönnblom (Sweden)
Jane Salmon (USA)
Georg Schett (Germany)
José da Silva (Portugal)
Hendrik Schulze-Koops (Germany)
Nan Shen (China)
Alexander So (Switzerland)
Tuulikki Sokka (Finland)
Deborah Symmons (UK)
Tsutomu Takeuchi (Japan)
Yoshiya Tanaka (Japan)
Alan Tyndall (Switzerland)
John Varga (USA)
Dimitrios Vassilopoulos (Greece)
Douglas Veale (Ireland)
Jiri Vencovsky (Czech Republic)
Ronald van Vollenhoven (Sweden)
Michael Ward (USA)
Kevin Winthrop (USA)
Kazuhiko Yamamoto (Japan)

Stefan Lohmander (Sweden)
Sir Ravinder Maini (UK)
Emilio Martín-Mola (Spain)
Haralampos Moutsopoulos (Greece)
James O'Dell (USA)
Karel Pavelka (Czech Republic)
Leo van de Putte (The Netherlands)
Jozef Rovensky (Slovakia)
Yehuda Shoenfeld (Israel)
Josef Smolen (Austria)
Walther van Venrooij (The Netherlands)
Michael Weinblatt (USA)
Frank Wollheim (Sweden)
Anthony Woolf (UK)

Contact Details

Editorial Office

Annals of the Rheumatic Diseases
 BMJ Publishing Group Ltd
 BMA House
 Tavistock Square
 London WC1H 9JR, UK
 T: +44 (0)20 7383 6250
 E: ard@bmj.com

Permissions

<http://www.bmj.com/company/products-services/rights-and-licensing/permissions>

Supplement Enquiries

T: +44 (0)20 7383 6057
 E: journals@bmj.com

Subscriptions

For all subscription enquiries and orders
 T: +44 (0)20 7111 1105
 E: <http://ard.bmj.com/pages/subscribe>

Display Advertising Sales

Sophie Fitzsimmons
 T: +44 (0)20 7383 6783
 E: sfztsimmons@bmj.com
<http://www.bmj.com/company/raise-visibility-and-reach>

Online Advertising Sales

Marc Clifford
 T: +44 (0) 20 7383 6161
 E: mclifford@bmj.com
<http://www.bmj.com/company/raise-visibility-and-reach>

Display & Online Advertising Sales (USA)

American Medical Communications (AMC)
 T: +1 732 490 5530
 E: jloughran@americanmedicalcomm.com

Author Reprints

Reprints Administrator
 E: admin.reprints@bmj.com

Commercial Reprints (except USA & Canada)

Nadia Gurney-Randall
 T: +44 (0)20 8445 5825
 M: +44 07866 262344
 E: ngurneyrandall@bmj.com

Commercial Reprints (USA & Canada)

Ray Thibodeau
 T: +1 267 895 1758
 M: +1 215 933 8484
 E: ray.thibodeau@contentednet.com

EULAR

EULAR Executive Secretariat
 Seestrasse 240, 8802 Kilchberg, Switzerland
 E: eular@eular.org
www.eular.org

For all other ARD contacts

<http://ard.bmj.com/contact-us>

Subscription Information

ARD is published monthly; subscribers receive all supplements
 ISSN 0003-4967 (print); 1468-2060 (online)

Institutional Rates 2017

Print
 £939; US\$1832; €1268

Online

Site licences are priced on FTE basis and allow access by the whole institution. Details available online at <http://journals.bmj.com/content/subscribers> or contact the Subscription Manager in the UK (see above right)

Personal print or online only and institutional print subscriptions may be purchased online at <http://journals.bmj.com/content/subscribers> (payment by Visa/Mastercard only)

Residents of some EC countries must pay VAT; for details, call us or visit <http://journals.bmj.com/content/subscribers>

Personal Rates 2017

Print (includes online access at no additional cost)
 £387; US\$755; €523

Online only
 £164; US\$320; €222

EULAR congress delegates

Delegates receive a Continuous Professional Development package that includes a 12 month complimentary subscription to ARD in print and/or online

Table 1. Characteristics of patients

	All patients (n=26)	MTX only (n=9)	Anti-TNF α (n=17)	p
Age (years)	51.9 \pm 15.4	60.0 \pm 15.1	47.7 \pm 13.8	0.056
Sex (Female :Male)	21:5	6:3	15:2	0.331
Disease duration (years)	6.5 \pm 5.4	7.5 \pm 5.0	5.7 \pm 5.6	0.518
BMI (kg/m 2)	28.3 \pm 7.1	25.2 \pm 5.1	30.1 \pm 7.6	0.109
DAS28 -ESR	4.27 \pm 2.03	2.17 \pm 0.53	5.79 \pm 1.08	<0.001
DAS28 -CRP	3.82 \pm 1.88	1.93 \pm 0.61	5.19 \pm 1.09	<0.001

increases in erosion volume at MCH2 and wrist despite low disease activity (Fig. B). In the anti-TNF α group, joint space width and volume of the MCP joints decreased significantly from BL to 3M and were positively correlated with erosion volume changes. Although microstructural parameters at the wrist and MCP remained largely unchanged, erosion volume changes were significantly negatively correlated with changes of trabecular BMD in the anti-TNF α group (Fig. C). No significant correlations were observed between HR-pQCT parameters and RAMRIS and DAS scores.




Figure. (A) Comparisons of changes of DAS 28 ESR and CRP from baseline (BL) to 3-months (3M). (B) Comparisons of changes of bone microarchitecture parameters from BL to 3M. *p<0.05; paired T test. (C) Spearman correlations between changes of erosion volume and each bone parameter in MCP in the anti-TNF α group

Conclusions: We found that anti-TNF α treatment can prevent erosion progression and deterioration of bone microarchitecture within the first 3 months of treatment. HR-pQCT can serve as a sensitive and powerful tool to quantify bone changes and monitor RA treatment even over short time periods.

References:

- [1] Barnabe C et al. Nat Rev Rheumatol. 2015.
- [2] Tam LS et al. J Rheumatol. 2016.
- [3] Moller U et al. Ann Rheum Dis. 2009.
- [4] Srikhun W et al. J Rheumatol. 2013.
- [5] Yang H et al. Int J Rheum Dis. 2015.
- [6] Burghardt AJ et al. Ann Biomed Eng. 2013.

Acknowledgements: The study was supported by UCB Pharma Inc.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.5321

OP0021 EFFICACY AND SAFETY RESULTS OF A PHASE III STUDY COMPARING FKB327, AN ADALIMUMAB BIOSIMILAR, WITH THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

R. Alten¹, J. Glover², N. Matsunaga³, D. Chisholm⁴, M. Genovese⁵. ¹University Medicine Berlin, Berlin, Germany; ²Coephycient Pharmaceutical Consultancy, Guildford, United Kingdom; ³Fujifilm Kyowa Kirin Biologics, Chiyoda-ku, Tokyo, Japan; ⁴Fujifilm Kyowa Kirin Biologics, Galashiels, United Kingdom; ⁵Stanford University, Palo Alto, CA, United States

Background: FKB327 is a proposed biosimilar of the adalimumab reference product (ADL). This randomised, double-blind, Phase III study (NCT02260791; FKB327-002) evaluated the therapeutic equivalence of FKB327 and ADL in patients (pts) with active rheumatoid arthritis (RA) inadequately controlled on methotrexate (MTX).

Objectives: To assess the efficacy, safety, pharmacokinetics (PK) and immunogenicity of FKB327 compared with ADL in pts with active RA.

Methods: Pts aged \geq 18 years with moderate to severe, active RA for \geq 3 months and taking MTX for \geq 3 months (10–25 mg/week [wk] stable dose for \geq 8 wks) were enrolled. Pts were randomised 1:1 to receive FKB327 or ADL (40 mg subcutaneous injection) every 2 wks with continuing MTX, stratified by prior biologic treatment (yes/no) and screening disease activity (Disease Activity Score 28 using C-reactive protein [DAS28-CRP] \leq 5.1/ $>$ 5.1). The primary efficacy endpoint was American College of Rheumatology (ACR) 20 response rate at Wk 24; equivalence margins of \pm 13% were prespecified for a two-sided 95% confidence interval (CI) based on ADL treatment effect in previous studies. Secondary endpoints included ACR20 response rate over time, DAS28-CRP at Wk 24 and over time. Safety was assessed by the incidence/severity of adverse events (AEs) and laboratory abnormalities.

Results: 730 pts from 105 sites in 12 countries were randomised; 728 pts were treated with either FKB327 (n=366) or ADL (n=362). Demographics and baseline RA characteristics were comparable between the groups, with overall mean age of 55.3 years, mean DAS28-CRP score of 6.1 and mean MTX dose of 15.7 mg/wk. ACR20 response rates at Wk 24 (full analysis set) were comparable between the FKB327 (270/363; 74.4%) and ADL groups (271/358; 75.7%). 95% CIs for treatment difference (FKB327 – ADL: –7.6 to 5.0) fell within the \pm 13% equivalence margins, meeting the primary study objective. ACR20 response rates over time overlapped during Wks 4–24 (Figure 1). Least squares mean DAS28-CRP at Wk 24 were 3.43 on FKB327 and 3.42 on ADL and were equivalent using prespecified margins; changes in scores over time were also comparable. The proportions of pts reporting treatment-emergent AEs (TEAEs) on FKB327 or ADL were similar (FKB327 55.5% vs ADL 61.6%); AEs were mainly mild or moderate. The most common TEAEs (\geq 5%) were nasopharyngitis (7.1% vs 8.0%) and upper respiratory tract infection (3.6% vs 5.0%). Incidences of serious AEs were similar (4.1% vs 5.2%). One death due to treatment-related disseminated tuberculosis (TB) was reported in the FKB327 group; reports of active TB were slightly higher with ADL (1 vs 3 pts). Mean serum trough concentration-time profiles of the two groups were comparable. The prevalence and titres of antidrug antibodies (ADA) were similar, including at final sampling (57.9% vs 55.8%).

Figure 1. ACR20 response rate by time (full analysis set)




Figure 1

Conclusions: The study met its prespecified equivalency endpoint for ACR20 response rate at Wk 24, with comparable rates over time. Safety profiles, ADA formation and PK were also similar, supporting the comparability of FKB327 and ADL in pts with active RA.

Disclosure of Interest: R. Alten Consultant for: Fujifilm Kyowa Kirin Biologics Co., Ltd, J. Glover Consultant for: Fujifilm Kyowa Kirin Biologics Co., Ltd, N. Matsunaga Employee of: Fujifilm Kyowa Kirin Biologics Co., Ltd, D. Chisholm Employee of: Fujifilm Kyowa Kirin Biologics Co., Ltd, M. Genovese Consultant for: Fujifilm Kyowa Kirin Biologics Co., Ltd, Abbvie, Amgen, Boehringer Ingelheim, Pfizer, Samsung Bioepis

DOI: 10.1136/annrheumdis-2017-eular.2220